It has been recently suggested that the risk of graft loss after liver transplantation (LT) may increase in female HCV patients. The aim of the study was to examine gender differences in HCV therapy tolerance and outcome in LT patients treated for HCV recurrence. A retrospective study was conducted on liver recipients with HCV recurrence, who were given antiviral therapy from 2001 to 2009 in 12 transplant centers in Italy. Sustained virological response (SVR), adherence-to-therapy, and side effects were evaluated. A multivariate logistic regression model was used after adjusting for possible confounders. The data regarding 342 treated patients were analyzed. SVR was reported in 38.8% of patients. At baseline, male and female did not differ in HCV viral load, histology, or rate of diabetes. SVR was lower in females than in males (29.5% vs. 42.1%; P=0.03). Adherence-to-therapy was also lower in females than in males 43.4% vs. 23.8%; P=0.001); anemia was the main reason for lower adherence. In a multivariate analysis in patients Genotype1, female gender (P<0.04), early virological response (P<0.0001), and adherence to therapy (P<0.0001) were independent predictors for SVR. In conclusion, female gender represents an independent negative prognostic factor for the outcome of HCV antiviral therapy after LT.

Giannelli, V., Giusto, M., Farcomeni, A., Ponziani, F., Pompili, M., Viganò, R., et al. (2012). Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. TRANSPLANT INTERNATIONAL, 25(4), 448-454 [10.1111/j.1432-2277.2012.01440.x].

Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients

Fagiuoli S;
2012

Abstract

It has been recently suggested that the risk of graft loss after liver transplantation (LT) may increase in female HCV patients. The aim of the study was to examine gender differences in HCV therapy tolerance and outcome in LT patients treated for HCV recurrence. A retrospective study was conducted on liver recipients with HCV recurrence, who were given antiviral therapy from 2001 to 2009 in 12 transplant centers in Italy. Sustained virological response (SVR), adherence-to-therapy, and side effects were evaluated. A multivariate logistic regression model was used after adjusting for possible confounders. The data regarding 342 treated patients were analyzed. SVR was reported in 38.8% of patients. At baseline, male and female did not differ in HCV viral load, histology, or rate of diabetes. SVR was lower in females than in males (29.5% vs. 42.1%; P=0.03). Adherence-to-therapy was also lower in females than in males 43.4% vs. 23.8%; P=0.001); anemia was the main reason for lower adherence. In a multivariate analysis in patients Genotype1, female gender (P<0.04), early virological response (P<0.0001), and adherence to therapy (P<0.0001) were independent predictors for SVR. In conclusion, female gender represents an independent negative prognostic factor for the outcome of HCV antiviral therapy after LT.
Articolo in rivista - Articolo scientifico
adherence; antiviral treatment; gender; HCV; liver transplant;
English
2012
25
4
448
454
reserved
Giannelli, V., Giusto, M., Farcomeni, A., Ponziani, F., Pompili, M., Viganò, R., et al. (2012). Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. TRANSPLANT INTERNATIONAL, 25(4), 448-454 [10.1111/j.1432-2277.2012.01440.x].
File in questo prodotto:
File Dimensione Formato  
GIANNELLI 2012.pdf

Solo gestori archivio

Dimensione 63.84 kB
Formato Adobe PDF
63.84 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/353941
Citazioni
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 7
Social impact